Real-World Evidence

Care Pathways Optimization

Providing a full spectrum of real-world evidence services

As part of Alira Health, the Care Factory team supports clients in all aspects of care pathways optimization, including:
  • Design of data models and study methodologies, including data set definition and analytics methodologies
  • Management of the SNDS process, including protocol of research, and procedure follow-up for the CESREES and CNIL
  • Data management and implementation of methodologies
  • Design of new remuneration models, including type of model (e.g., risk sharing performance), trackers, indicators, and methodologies
  • Impacts modeling and comparisons with existing solutions
  • Managing experts throughout the process

Data collection and sourcing

We collect the following data

  • Patient profiles, including age, gender, and welfare
  • Disease information, including diagnostic and co-morbidities
  • Drug prescriptions
  • Claims

Through these sources

  • Literature
  • Practitioners or coding expert interviews
  • SNIIRAM (event and total costs of care), EGB
  • PMSI (event during hospital stays)
  • CEPIDC (deceased cause)
  • Open data (open DAMIR)

Why partner with Alira Health and Care Factory?

Together, Alira Health and Care Factory provide services across the ecosystem for members of the healthcare industry looking to value the efficacy of care.

As innovative, market leaders in real-world evidence and data collection, we work closely with clients looking to experiment with new remuneration models, including performance, episodes, and yearly fees.

Care Pathways Optimization

Related News

Publications September 20, 2023
Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates
Our expert CMC team addresses the manufacturing challenges of ADCs in “Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates.”
CMC Drug Development
Publications September 20, 2023
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
The NICE recommended routine funding for TRANSLARNA (ataluren) to treat Duchenne Muscular Dystrophy (DMD), based on RWE combined with feedback from patients, caregivers, and clinicians.
Real-World Evidence (RWE) RWE Decision Alert
Publications September 19, 2023
Opportunities and Challenges in the Therapeutic and CDMO Markets
Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth in this CHEManager article.
CDMO Pharma
Publications September 15, 2023
Leveraging a Virtual Site to Boost Diversity and Enrollment
The client’s study aimed to assess the sensitivity and specificity of a novel diagnostic test for colorectal cancer in a large population representative of the diversity in the US.(...)
Biotech
Publications September 12, 2023
Global MedTech CDMO M&A Update
Discover key market insights, deal activities and their implications, and factors driving the growth and evolution of the global CDMO market.
CDMO
News September 8, 2023
Alira Health Partners With Col·legi de Metges de Barcelona
We are pleased to partner with Col·legi de Metges de Barcelona (CoMB), an institution that represents and serves the almost 39,000 physicians in Barcelona.
Market Access Spain Startups
Blog September 6, 2023
Execution: How Biotechs Can Plan and Run Successful Clinical Trials
Biotech experts Joris Pezzini and Chris Rao answer questions about the challenges of executing a successful clinical trial.
Biotech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.